Kiniksa Pharmaceuticals International, plc (KNSA) Financial Statements — Income, Balance Sheet, Cash Flow

Overview Financials Chart Business Summary Filings Ownership Valuation

Financial Statements — KNSA

Balance Sheet

(in millions USD)

Metric	Q1 2026	Q3 2025	Q2 2025	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022	Q2 2022	Q1 2022	Q3 2021	Q2 2021	Q1 2021
Cash & Equivalents	189.95	174.86	192.04	157.13	97.38	99.27	141.08	117.83	112.57	80.62	175.76	94.31	63.32	190.18	167.95	119.86
Short-term Investments	278.14	177.24	115.75	111.21	126.40	119.49	72.47	83.26	72.43	106.88	24.96	43.90	82.25	10.00	57.91	144.17
Accounts Receivable	23.22	51.74	31.91	40.07	24.89	20.45	16.00	3.04	24.65	7.42	11.16	7.81	29.44	3.22	2.55	--
Inventory	73.14	41.40	48.18	22.07	28.68	34.86	27.28	25.58	23.96	23.43	14.62	19.92	13.22	5.61	6.38	2.19
Total Current Assets	594.17	475.53	420.31	355.91	311.30	301.02	270.59	256.11	246.04	231.50	241.82	179.94	198.76	217.51	244.81	275.56
Property, Plant & Equipment	1.99	1.66	1.08	0.61	0.56	0.63	0.71	0.92	1.14	1.39	2.00	2.15	2.48	3.17	3.45	3.82
Intangible Assets	15.00	15.50	15.75	16.00	16.50	16.75	17.00	17.50	17.75	18.00	18.50	18.75	19.00	19.50	19.75	20.00
Total Non-current Assets*	231.11	236.80	240.84	243.42	244.00	241.41	249.08	226.95	238.29	211.36	218.14	30.64	32.21	35.35	34.40	35.59
Total Assets	825.28	712.33	661.15	599.33	555.30	542.43	519.67	483.06	484.33	442.86	459.95	210.58	230.97	252.86	279.21	311.16
Accounts Payable	24.40	6.15	8.96	1.98	8.33	7.39	5.63	1.01	0.65	1.39	1.47	2.52	3.38	1.65	4.16	2.76
Total Current Liabilities	156.61	123.59	117.83	97.27	95.96	84.29	64.21	53.47	47.47	36.59	56.49	43.54	50.35	34.43	38.78	35.45
Total Non-current Liabilities*	62.98	53.36	48.32	44.57	22.34	23.04	23.57	24.47	25.20	16.18	19.45	13.54	14.37	4.38	4.64	5.01
Total Liabilities	219.59	176.95	166.14	141.84	118.29	107.33	87.78	77.94	72.68	52.77	75.94	57.08	64.72	38.81	43.42	40.46
Retained Earnings	(439.55)	(476.34)	(494.77)	(512.60)	(512.25)	(499.56)	(495.65)	(503.19)	(489.33)	(504.30)	(496.49)	(720.59)	(700.61)	(639.06)	(608.52)	(566.96)
Total Stockholder Equity	605.69	535.38	495.01	457.49	437.01	435.10	431.90	405.13	411.66	390.10	384.01	153.49	166.24	214.05	235.79	270.70

* Derived from reported values

Income Statement

(in millions USD) (except per-share rows)

Metric	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022	Q4 2021	Q3 2021	Q2 2021
Total Revenue	214.27	202.13	180.86	156.80	137.79	122.54	112.21	108.63	79.86	83.40	67.05	71.47	48.35	61.88	99.14	26.97	32.19	18.75	12.10	7.70
Cost of Revenue*	20.80	20.95	20.26	18.60	17.87	17.90	20.11	12.32	10.58	9.58	9.09	7.70	7.04	6.71	6.94	(22.94)	--	3.87	2.77	2.47
Gross Profit	193.47	181.18	160.60	138.19	119.92	104.64	257.69	165.58	69.28	73.81	57.96	63.77	41.31	55.17	92.20	49.91	--	14.88	9.33	5.24
Research & Development	27.48	34.61	24.17	18.75	19.33	35.22	26.06	24.02	26.33	20.05	17.11	23.77	15.17	14.39	16.49	13.80	20.82	27.43	19.24	23.95
Selling, General & Admin	61.15	56.78	49.10	46.86	43.53	40.53	46.40	42.40	38.68	36.74	34.47	29.18	29.05	27.22	24.68	23.84	22.22	22.74	20.76	21.85
Total Operating Expenses	164.20	161.41	136.58	118.03	106.65	123.94	284.01	182.24	85.82	73.73	68.89	66.93	52.51	49.13	45.79	92.60	--	51.01	39.99	45.79
Operating Income	29.27	19.77	24.02	20.16	13.27	(19.30)	(9.66)	(0.12)	(16.54)	0.08	(10.93)	(3.15)	(11.20)	6.05	46.41	(19.37)	(23.32)	(36.13)	(30.67)	(40.55)
Pretax Income	32.68	23.27	27.16	22.88	15.57	(16.98)	(7.20)	2.30	(14.28)	2.45	(8.50)	(1.24)	(9.36)	6.84	46.74	(19.26)	(23.28)	(36.05)	(30.66)	(40.55)
Tax Provision	10.09	9.07	8.72	5.05	7.03	(8.09)	5.49	6.21	3.43	(22.79)	5.36	(16.21)	2.91	2.38	(177.36)	0.72	1.93	0.28	(0.12)	1.01
Net Income	22.59	14.20	18.43	17.83	8.54	(8.89)	(12.69)	(3.91)	(17.70)	25.24	(13.85)	14.97	(12.27)	4.46	224.09	(19.98)	(25.21)	(36.33)	(30.54)	(41.56)
Basic EPS	0.30	0.19	0.25	0.24	0.12	(0.11)	(0.18)	(0.06)	(0.25)	0.37	(0.20)	0.21	(0.18)	0.06	3.23	(0.29)	(0.36)	(0.53)	--	--
Diluted EPS	0.27	0.18	0.23	0.23	0.11	(0.11)	(0.18)	(0.06)	(0.25)	0.37	(0.20)	0.21	(0.18)	0.07	3.18	(0.29)	(0.36)	(0.53)	--	--

* Derived from reported values

Cash Flow Statement

(in millions USD)

Metric	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022	Q4 2021	Q3 2021	Q2 2021
Operating Cash Flow	50.20	53.89	33.68	28.09	22.32	18.77	(2.24)	5.17	3.99	4.33	16.99	(3.74)	(4.27)	(11.58)	62.05	(7.82)	(36.85)	(18.88)	(28.51)	(38.78)
Capital Expenditures	0.16	0.63	0.67	0.17	0.10	0.19	0.00	0.00	0.08	0.06	0.02	0.03	0.02	(0.03)	0.02	0.12	--	0.25	0.05	0.06
Free Cash Flow*	50.04	53.26	33.01	27.93	22.23	18.58	(2.24)	5.17	3.90	4.27	16.97	(3.78)	(4.29)	(11.54)	62.03	(7.94)	--	(19.14)	(28.56)	(38.84)
Investing Cash Flow	(31.92)	(70.81)	(62.75)	(3.88)	(51.54)	65.29	(6.35)	(46.80)	25.52	(14.89)	(12.28)	35.53	(37.92)	(42.66)	19.04	38.27	(22.72)	(50.04)	47.85	85.99
Financing Cash Flow	6.07	7.66	11.90	10.70	2.77	2.14	6.69	(0.18)	3.61	0.70	0.55	0.16	0.09	1.19	0.36	0.54	0.42	1.21	2.68	0.89

* Derived from reported values